"Quantum Pharma plc, the service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has announced today that Biodose Connect® has received Class I medical device status from the MHRA (meaning it now has CE Mark authorisation). Biodose Connect® remotely monitors the use of Quantum’s Biodose trays (each of which holds 28 individually sealed medicine pods) and will assist patients, their carers and clinicians to ensure that medications are being taken as prescribed..." - from a note out this morning by Zeus, it's on Research Tree
Zeus' note out this morning on Research Tree... "As expected, Vertu is deploying the equity capital from the placing quickly, this time acquiring a long established business comprising of five outlets in Chesterfield and Derby. This is a strong geographic region for the Group and adds further scale to its Land Rover, Skoda and Nissan franchise. In addition, this also adds Toyota as a new brand partner. We anticipate this transaction to be EPS enhancing from the outset, and believe Vertu has acquired this for an EV/EBITDA multiple of 6x, which is in line with its stated..."
"To date, SEMS Exploration Services Limited has completed approximately 40 line kilometres of the planned 80 line kilometres of the Induced Polarisation (IP) survey now underway on the Ferensola license in Sierra Leone of Sula Iron and Gold (SULA). Seven survey lines over the target area previously drilled at Sanama Hill (The target resource area of prior press releases) indicate a relationship between chargeability anomalies, indicative of sulphide mineralisation, present in the vicinity of the drilled gold intercepts. It is clear that additional and significant anomalies are being identified, particularly to the east on sections completed so far. SULA acknowledges that the presence of an IP anomaly does not confirm the presence of gold mineralisation, however, the strength of the IP...."
Panmure note from Research Tree... We make some slight changes to our Aveva forecasts in the wake of the analyst 'surgery' on Friday last. Whilst the surgery contained little new news, it helped to clarify our thinking. As we suspected, no special dividend, as Aveva would prefer to retain cash for a potential acquisition. There is also a CMD in the early stages of being planned, think early Autumn, then Aveva will discuss its product plans for its cloud initiative. Finally it was a positive that the management team seems to have a better grasp on its markets.
Panmure published a note this morning... Eland reported a net loss for FY15 of US$6.8m, less than half that of FY14, on higher revenue and lower costs. After deducting non-controlling interests, the company generated earnings per share of US$0.13 (FY14 US$0.07), well ahead of our US$0.08 estimate. Following the successful US$18.5m equity raise, Eland could exit this year with net production of around 10kbd, on completion of the Gbetiokun and Ubima Early Production Systems (EPS). The FY16 revenue outturn remains subject to restart of the Forcados export system. It's available on Research Tree
Just pulled this from ResearchTree... Bad news released just before a 3 day weekend is typically about as welcome as a soggy bank-holiday break. That said, any sharp fall in shares can offer good opportunities for risk-tolerant investors prepared to take advantage of any over-reaction.
VSA published a note this morning, it's on Research Tree... Asiamet Resources (ARS) reports total expenses for the quarter ended March 31 of US$0.69m while raising post quarter end £1.5m (cUS$2.2m) to offset a working capital deficit carried into the current quarter of US$0.15m. In addition, a further US$0.98m has been received from the Indonesian government for refund of VAT. ARS published a robust PEA concerning developing the Beruang Kanan project to a producing copper mine during the quarter.
Stockdale's note from this morning... Proton Power Systems (PPS) has signed a seven year framework agreement worth €15m with a blue chip German customer for fuel cell emergency power units. These are expected to be delivered and installed over a seven year period. This follows the first binding order received in April 2016 from the customer worth €1.8m in 2016. As this agreement covers only one of Germany’s regions there is potential for it to grow substantially. We view this news positively and will reinstate formal research coverage in due course. It's up on Research Tree.
Stockdale published a note this morning too, it's also on Research Tree.. The key financial highlight in 2015 was raising £20m net through a fund-raising at 8p per share in May. This has enabled Advanced Oncotherapy (AVO) to progress its project to have the first commercial LIGHT system deployed in Harley Street in 2017. Last week’s news of a financing agreement between AVO and Metric Capital ensures the finances are in place to complete this. We shall publish an updated research report with detailed forecasts in due course but ahead of that.